.png)
MicroMediome Selected as Resident Startup at Seoul Bio Hub
- wonsucky
- Apr 21
- 1 min read
MicroMediome Selected as Resident Startup at Seoul Bio Hub
MicroMediome has been selected as one of 12 promising startups to join Seoul Bio Hub’s ‘Bio-Medical R&D Anchor Facility’ program, supported by the city of Seoul and KIST.
This selection highlights MicroMediome’s innovation in microbiome-based therapeutics, recognizing its potential to lead the future of bio-health.
As a resident company, MicroMediome will gain access to advanced research labs, shared equipment, and strategic support in investment, global expansion, and industry collaboration.
